A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Public ClinicalTrials.gov record NCT06885034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Study identification
- NCT ID
- NCT06885034
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 451 participants
Conditions and interventions
Conditions
Interventions
- Risvutatug Rezetecan Biological
- Drug 1 Drug
- Drug 2 Drug
- Drug 3 Drug
- Drug 4 Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2025
- Primary completion
- Jan 9, 2028
- Completion
- Jan 8, 2029
- Last update posted
- Aug 2, 2026
2025 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Los Alamitos | California | 90505 | Recruiting |
| GSK Investigational Site | Los Angeles | California | 90089 | Recruiting |
| GSK Investigational Site | Santa Monica | California | 90404 | Recruiting |
| GSK Investigational Site | Whittier | California | 90602 | Recruiting |
| GSK Investigational Site | Aurora | Colorado | 80045 | Recruiting |
| GSK Investigational Site | New York | New York | 10021 | Recruiting |
| GSK Investigational Site | New York | New York | 10065 | Recruiting |
| GSK Investigational Site | Durham | North Carolina | 27710 | Recruiting |
| GSK Investigational Site | Houston | Texas | 77479 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78229 | Recruiting |
| GSK Investigational Site | Wenatchee | Washington | 98801 | Recruiting |
| GSK Investigational Site | Madison | Wisconsin | 53792-0001 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06885034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06885034 live on ClinicalTrials.gov.